BMS Consensus Statement: Non-hormonal-based Treatments for Menopausal Symptoms (July 2026)

Tier 2: Professional organization or credentialed expert guidance
Publisher: British Menopause Society · Published: July 1, 2026 · Accessed: September 4, 2026

Visit the source ↗

Claims this source supports

• The British Menopause Society (July 2026 consensus): many women look for non-hormonal options, some cannot take hormonal therapies, and greater clinical experience with women who have had breast cancer is improving the evidence for how to manage them with individualized holistic plans.
• Prescribable non-hormonal therapies with randomized placebo-controlled trial evidence for vasomotor symptoms include paroxetine, fluoxetine, citalopram, escitalopram, venlafaxine, desvenlafaxine, gabapentin, pregabalin, clonidine, fezolinetant, and elinzanetant; no non-hormonal treatment is as effective as estrogen.
• Placebo responses in vasomotor-symptom trials can be as high as 30-50%; self-help options used for vasomotor control include CBT, targeted self-hypnosis, isoflavones, and herbal therapies, with variable evidence.
• In the USA, paroxetine received FDA approval for menopausal hot flushes in 2015.